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528 Early outcomes in human lung transplantation with Thymoglobulin or
Campath-1H for recipient pretreatment followed by posttransplant
tacrolimus near-monotherapy
Kenneth R. McCurry, MD, Aldo Iacono, MD, Adrianna Zeevi, PhD, Samuel Yousem, MD,
Alin Girnita, MD, Shahid Husain, MD, Diana Zaldonis, BSN, Bruce Johnson, MD,
Brack G. Hattler, MD, and Thomas E. Starzl, MD, PhD, Pittsburgh, Pa
Instead of conventional multiple drug prophylactic immunosuppression, 48 lung recipients were
pretreated with Thymoglobulin (rabbit antithymocyte globulin; n  38) or Campath
(alemtuzumab; n  10) and maintained postoperatively with tacrolimus monotherapy. Patient
and graft survival and quality of life were equivalent to that previously attainable. This strategy
might improve results in lung transplantation.
538 Long-term survival in lung transplant recipients after successful
preoperative coronary revascularization
Leonardo Seoane, MD, Lee M. Arcement, MD, Vincent G. Valentine, MD, and
P. Michael McFadden, MD, New Orleans, La
Despite increased dysrhythmias and older age, lung transplant recipients with revascularized
coronary arteries have long-term survival similar to that of those with normal coronary arteries.
Compared with the revascularized group, survival is worse in lung transplant recipients with
insignificant CAD, for whom optimal management requires further study.
542 Cardiac retransplantation in childhood: Analysis of data from the United
Network for Organ Sharing
William T. Mahle, MD, Robert N. Vincent, MD, and Kirk R. Kanter, MD, Atlanta, Ga
We reviewed outcomes of 219 children who underwent cardiac transplantation from 1987 to
2004. Five-year survival was significantly less after retransplantation than after primary
transplantation, with risk factors for death after retransplantation being pretransplant mechanical
ventilation and early primary graft failure. In the setting of limited organ availability, the
strategy of retransplantation requires careful consideration.
547 Stem cell therapy in the aging hearts of Fisher 344 rats: Synergistic effects
on myogenesis and angiogenesis
Jiang-Yong Min, MD, Yu Chen, MD, Sohail Malek, BS, Achim Meissner, MD,
Meixiang Xiang, MD, PhD, Qinen Ke, MD, Xin Feng, MD, Masaharu Nakayama, MD, PhD,
Emel Kaplan, MD, and James P. Morgan, MD, PhD, Boston, Mass, and Kiel, Germany
This study demonstrates that functional benefits from intramyocardial transplantation of stem
cells were associated with increased myocyte numbers and enhanced left ventricular blood flow
in the aging heart. Regenerating cardiomyocytes and increasing regional blood perfusion in the
aging heart after stem cell transplantation synergistically resulted in restoration of cardiac
reserve.
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